{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:15:22Z","timestamp":1794093322389,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed\/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8\n                    <jats:sup>+<\/jats:sup>\n                    CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-02129-y","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T08:02:24Z","timestamp":1704528144000},"page":"372-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma"],"prefix":"10.1038","volume":"38","author":[{"given":"Luise","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-4941","authenticated-orcid":false,"given":"Anne Sophie","family":"Kubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-8750","authenticated-orcid":false,"given":"Song Yau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Ussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kirchberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Hell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-2332","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-4872","authenticated-orcid":false,"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356. https:\/\/pubmed.ncbi.nlm.nih.gov\/30501490\/.","journal-title":"N Engl J Med"},{"key":"2129_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2023.04.003","volume":"29","author":"L Shiqi","year":"2023","unstructured":"Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, et al. Durable remission related to CAR-T persistence in R\/R B-ALL and long-term persistence potential of prime CAR-T. Mol Ther Oncolytics. 2023;29:107\u201317. https:\/\/pubmed.ncbi.nlm.nih.gov\/37215385\/.","journal-title":"Mol Ther Oncolytics"},{"key":"2129_CR3","doi-asserted-by":"crossref","unstructured":"Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020;5. https:\/\/pubmed.ncbi.nlm.nih.gov\/32484797\/.","DOI":"10.1172\/jci.insight.134612"},{"key":"2129_CR4","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","volume":"5","author":"S Faude","year":"2021","unstructured":"Faude S, Wei J, Muralidharan K, Xu X, Wertheim G, Paessler M, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 2021;5:2128\u201336. https:\/\/pubmed.ncbi.nlm.nih.gov\/33881465\/.","journal-title":"Blood Adv"},{"key":"2129_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531\u201344. https:\/\/pubmed.ncbi.nlm.nih.gov\/29226797\/.","journal-title":"N Engl J Med"},{"key":"2129_CR6","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/22160384\/.","journal-title":"Blood"},{"key":"2129_CR7","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","volume":"5","author":"FA Ayuk","year":"2021","unstructured":"Ayuk FA, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Adv. 2021;5:2523\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/34100900\/.","journal-title":"Blood Adv"},{"key":"2129_CR8","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267\u201380. https:\/\/pubmed.ncbi.nlm.nih.gov\/29812997\/.","journal-title":"J Clin Oncol"},{"key":"2129_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet [Internet] 2021;398:314\u201324. https:\/\/pubmed.ncbi.nlm.nih.gov\/34175021\/.","journal-title":"Lancet [Internet]"},{"key":"2129_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/pubmed.ncbi.nlm.nih.gov\/33626253\/.","journal-title":"N Engl J Med"},{"key":"2129_CR11","doi-asserted-by":"crossref","unstructured":"Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, et al. Advanced flow cytometry assays for immune monitoring of CAR-T cell applications. Front Immunol. 2021;12. https:\/\/pubmed.ncbi.nlm.nih.gov\/34012442\/.","DOI":"10.3389\/fimmu.2021.658314"},{"key":"2129_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cytob.21162","volume":"86","author":"A Boldt","year":"2014","unstructured":"Boldt A, Borte S, Fricke S, Kentouche K, Emmrich F, Borte M, et al. Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies. Cytom B Clin Cytom. 2014;86:191\u2013206. https:\/\/pubmed.ncbi.nlm.nih.gov\/24488780\/.","journal-title":"Cytom B Clin Cytom"},{"key":"2129_CR13","doi-asserted-by":"crossref","unstructured":"Sanoyan DA, Seipel K, Bacher U, Kronig MN, Porret N, Wiedemann G, et al. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients. BMC Cancer. 2023;23. https:\/\/pubmed.ncbi.nlm.nih.gov\/37061680\/.","DOI":"10.1186\/s12885-023-10824-3"},{"key":"2129_CR14","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24:6175\u201384. https:\/\/pubmed.ncbi.nlm.nih.gov\/30190371\/.","journal-title":"Clin Cancer Res"},{"key":"2129_CR15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317\u201325. https:\/\/pubmed.ncbi.nlm.nih.gov\/28935694\/.","journal-title":"Blood"},{"key":"2129_CR16","doi-asserted-by":"crossref","unstructured":"Beider K, Itzhaki O, Schachter J, Grushchenko-Polaq AH, Voevoda-Dimenshtein V, Rosenberg E, et al. Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies. Cells. 2022;11. https:\/\/pubmed.ncbi.nlm.nih.gov\/35406703\/.","DOI":"10.3390\/cells11071140"},{"key":"2129_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ymthe.2020.11.028","volume":"29","author":"X Li","year":"2021","unstructured":"Li X, Guo X, Zhu Y, Wei G, Zhang Y, Li X, et al. Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia. Mol Ther. 2021;29:645\u201357. https:\/\/pubmed.ncbi.nlm.nih.gov\/33278564\/.","journal-title":"Mol Ther"},{"key":"2129_CR18","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28:1848\u201359. https:\/\/pubmed.ncbi.nlm.nih.gov\/36097221\/.","journal-title":"Nat Med"},{"key":"2129_CR19","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA, Ram\u00edrez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13. https:\/\/pubmed.ncbi.nlm.nih.gov\/35572525\/.","DOI":"10.3389\/fimmu.2022.878209"},{"key":"2129_CR20","doi-asserted-by":"crossref","unstructured":"Guarini A, Radice G, Peragine N, Buracchi C, De Propris MS, Di Rocco A, et al. Long-term host immune modulation following tisagenlecleucel administration in patients with diffuse large B-cell lymphoma and B-lineage acute lymphoblastic leukemia. Cancers (Basel). 2023;15. https:\/\/pubmed.ncbi.nlm.nih.gov\/37173879\/.","DOI":"10.3390\/cancers15092411"},{"key":"2129_CR21","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3:2812\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/31575532\/.","journal-title":"Blood Adv"},{"key":"2129_CR22","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210\u201321. https:\/\/pubmed.ncbi.nlm.nih.gov\/30896447\/.","journal-title":"J Clin Invest"},{"key":"2129_CR23","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"DX Bu","year":"2018","unstructured":"Bu DX, Singh R, Choi EE, Ruella M, Cruz SN, Mansfield KG, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9:25764\u201380. https:\/\/pubmed.ncbi.nlm.nih.gov\/29899820\/.","journal-title":"Oncotarget"},{"key":"2129_CR24","doi-asserted-by":"crossref","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16. https:\/\/pubmed.ncbi.nlm.nih.gov\/37525244\/.","DOI":"10.1186\/s13045-023-01465-x"},{"key":"2129_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513. https:\/\/pubmed.ncbi.nlm.nih.gov\/34166502\/.","journal-title":"Blood"},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338. https:\/\/pubmed.ncbi.nlm.nih.gov\/30592986\/.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02129-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02129-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02129-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T06:06:39Z","timestamp":1707113199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02129-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02129-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3396454\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SF: Consultant and\/or speaker fees: Novartis Pharma GmbH, Janssen-Cilag GmbH, Vertex Pharmaceuticals (Germany) GmbH, Kite\/Gilead Sciences GmbH, MSGO GmbH, Bristol-Myers Squibb GmbH & Co. KGaA. UK: Consultant and\/or speaker fees: AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. KGaA. UP: Honoraria and research support: BMS, Johnson-Johnson, Gilead. MM: Advisory Boards\/Honoraria\/Research support: Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}